Benchmarking - Labeling of Marketed Products used in
Clinical Trials ( 63 KB)
Responses from EU IP COP SC members to the question: How do you deal with company sponsored studies phases
1-4 in cases you would use products with a marketing authorization in your studies? Would you label these
products? Would you consider additional labelling as necessary?